bioAffinity Technologies Raises $4M in Registered Direct Offering to Fuel Lung Cancer Test Growth
Event summary
- bioAffinity Technologies secures $4M in registered direct offering at $6.122 per share, with concurrent private placement of warrants.
- Proceeds earmarked for working capital and commercialization of CyPath® Lung, its noninvasive lung cancer detection test.
- Offering priced at-the-market under Nasdaq rules, expected to close October 9, 2026.
- WallachBeth Capital acts as sole placement agent for the transaction.
The big picture
This $4M capital raise underscores the growing investor interest in noninvasive diagnostics for early lung disease detection. As healthcare systems prioritize preventive care, bioAffinity's CyPath® Lung test could gain traction, but competition in diagnostics and reimbursement hurdles remain key challenges. The at-the-market pricing strategy reflects bioAffinity's need for flexible capital access while minimizing dilution.
What we're watching
- Commercialization Pace
- How quickly bioAffinity can translate $4M proceeds into CyPath® Lung sales growth and market penetration.
- Warrant Exercise
- Whether institutional investors will exercise warrants at $6.122, signaling confidence in bioAffinity's long-term prospects.
- Competitive Positioning
- The extent to which this funding round strengthens bioAffinity's lead in noninvasive lung disease diagnostics.
Related topics